STOCK TITAN

ReShape Lifesciences Inc. - $RSLS STOCK NEWS

Welcome to our dedicated page for ReShape Lifesciences news (Ticker: $RSLS), a resource for investors and traders seeking the latest updates and insights on ReShape Lifesciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ReShape Lifesciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ReShape Lifesciences's position in the market.

Rhea-AI Summary
ReShape Lifesciences Inc. (Nasdaq: RSLS) reported a 37% reduction in core operating expenses compared to the third quarter of 2022. A cost reduction plan aims to cut operating expenses by over 40% in 2024 compared to 2023. The company also highlighted a recent exclusive licensing agreement, a strengthened patent portfolio, and a successful public offering. The CEO emphasized the impact of GLP-1 adoption on the medical weight loss market and the company's strategic measures to address this, including significant cost cuts and investment in growth drivers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.06%
Tags
-
Rhea-AI Summary
ReShape Lifesciences Inc. will report its financial results for Q3 2023 on November 8, 2023. The company will also provide a corporate update. A conference call will be held at 5:00 pm ET on November 8, with a live webcast available on the company's website. Participants can access the call by phone and an archived replay will be available on the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
-
Rhea-AI Summary
ReShape Lifesciences® announces pricing of public offering of 9.1M units at $0.33 each, expecting gross proceeds of $3.0M
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.18%
Tags
Rhea-AI Summary
ReShape Lifesciences to present company overview at LD Micro's Annual Main Event, highlighting Lap-Band program and ReShapeCare virtual weight-management program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
none
-
Rhea-AI Summary
ReShape Lifesciences signs exclusive license agreement with Biorad Medysis to distribute Obalon Gastric Balloon System in Indian Subcontinent
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.35%
Tags
none
-
Rhea-AI Summary
ReShape Lifesciences strengthens patent portfolio for Obalon Balloon System, with one patent granted and two notices of allowance received
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.64%
Tags
none
Rhea-AI Summary
ReShape Lifesciences® receives $331,541 SBIR grant for development of DBSN™ device to treat Type 2 diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
ReShape Lifesciences Inc. reports financial results for Q2 2023, with a 53% reduction in operating expenses compared to last year. The company made operational improvements and invested in growth drivers. They signed a preferred partner agreement with Hive Medical for lead optimization software. They also submitted a PMA supplement application to the FDA for their next generation Lap-Band® 2.0. Revenue contracted in Q2 2023 compared to the same period last year, but the company expects growth in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
none
ReShape Lifesciences Inc.

Nasdaq:RSLS

RSLS Rankings

RSLS Stock Data

4.08M
20.82M
11.16%
1.97%
3.11%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SAN CLEMENTE

About RSLS

reshape medical is a development-stage medical device manufacturer headquartered in southern california. the company is focused on the development of non-surgical weight loss devices that can be used as aids in the treatment of obese or overweight patients. there are millions of people looking for a solution to assist them in their battle to lose weight, but many are afraid of the risks of surgery. previously, few if any options existed between drugs for weight loss and invasive surgical restructuring of the anatomy. reshape medical intends to broaden the options and is developing less invasive devices for weight loss treatment.